MPS Limited Q3 FY26 Earnings Call Transcript Released
MPS Limited released its Q3 FY26 earnings call transcript. For 9M FY26, revenue reached ₹563.2 crores. The company is acquiring Unbound Medicine for USD 16.5 million, expected to close by Feb 10, 2026. MPS projects surpassing ₹100 EPS in FY26 and anticipates an exceptional FY27.
The acquisition of Unbound Medicine for $16.5 million is a significant strategic move that is expected to be transformative for the company. Additionally, the positive outlook for FY26 and FY27, including surpassing EPS targets, indicates a high impact.
The company is confident about future performance, projecting to surpass ₹100 EPS in FY26 and expecting an exceptional FY27, supported by strategic acquisitions and business segment growth.
MPS Limited has released the transcript of its Earnings Conference Call held on February 02, 2026, discussing the Un-Audited Financial Results for the Third Quarter (Q3) and Nine Months ended December 31, 2025.
During the call, management provided insights into the company's performance across its business segments. For the first nine months of FY26, revenue grew to ₹563.2 crores, with Q3 revenue at ₹182.5 crores and an EBITDA margin of 31.6%. The Education Solutions segment showed strong growth at over 38% year-to-date, while Research Solutions remained a stable anchor, contributing 61.1% to the 9M FY26 revenue with 16.2% year-on-year organic growth. The Corporate Learning segment saw a pullback, which the company views as a tactical challenge to realign with higher-margin work.
The company also announced the definitive agreement for the acquisition of Unbound Medicine for a total consideration of USD 16.5 million, expected to close by February 10, 2026. This acquisition is seen as a transformative milestone, expanding the company's reach into the medical and nursing ecosystems with resilient, recurring revenue.
Looking ahead, MPS Limited is confident in surpassing an EPS of ₹100 in FY26 and expects to outperform Q3 benchmarks in Q4 FY26 as strategic changes take hold. The company anticipates FY27 to be an exceptional year, with stabilized revenue from AJE, continued double-digit growth in Education, return to growth in Corporate Learning, and synergies from the Unbound acquisition.
What to do with a filing like this
MPS Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by MPS Limited. Read the original for the full detail.